Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment
Authors' conclusion
The RAIR-TC molecular profile is heterogeneous with TERT being the most frequent mutation. Cases negative for all mutations and cases presenting the coexistence of TERT + driver mutation had a worse response to lenvatinib. Conversely, the presence of 1 driver mutation correlated with a better response to lenvatinib.
Study context
- Population
- Patients with advanced radioiodine-refractory thyroid cancer (RAIR-TC) treated with first-line lenvatinib and followed at least 1 year, referral center
- Participants
- 49 patients
- Exposure
- Molecular subgroups of RAIR-TC treated with first-line lenvatinib
- Outcome
- Mutational profile (next-generation sequencing)
- Follow-up
- Median 9.2 years (interquartile range 6-14.1)
Methodological detailssingle-centre, referral center
- Single-centre
- Referral center
Main finding
As reported in the abstract
- BRAF mutation
- 38.7%
- RAS mutation
- 22.4%
- TERT mutation
- 57.1%
- TP53 mutation
- 6.1%
- No driver mutations
- 34.6%
- Driver mutations co-occurring with TERT or TP53
- 44.9%
- No mutations
- 10/49 (20.4%)
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| PFS: ≥1 mutation vs negative for any mutationLonger PFS with ≥1 mutation | P = 0.004 |
| PFS by molecular groupGroup 1 vs Group 3 · longer PFS in group 1 | P = 0.04 |
| PFS by molecular groupGroup 1 vs Group 2 · no difference | P = 0.13 |
| OS by molecular groupGroup 1 vs Group 2 · longer OS in group 1 | P = 0.026 |
| OS by molecular groupGroup 1 vs Group 3 · longer OS in group 1 | P = 0.034 |
Progression-free survival (PFS) and overall survival (OS): BRAF-mutated and RAS-mutated vs wild-type
- Both BRAF-mutated and RAS-mutated cases showed better PFS and OS, not statistically significant vs wild-type
Original publication
Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment. J Clin Endocrinol Metab. Published 27 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →